Upon discovery, Crizotinib, a tyrosine kinase inhibitor targeting MET, ROS1 and ALK entered phase I trial which reported 72% 6-month progression-free survival and overall response of 57% in ALK positive NSCLC (12). This evidence concerns the gene ALK and non-small cell lung carcinoma.